Efficacy of Positron Emission Tomography Staging for Small-Cell Lung Cancer: A Systematic Review and Cost Analysis in the Australian Setting  by Ruben, Jeremy D. & Ball, David L.
e26 Copyright © 2012 by the International Association for the Study of Lung Cancer
Letters to the Editor  Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012
In Response:
We are grateful for the interest 
shown in our article by Drs. Faivre-Finn 
and Lorigan and for the points they 
raise about integrating positron emis-
sion tomography (PET) for small-cell 
lung cancer (SCLC) into clinical prac-
tice. We agree that the evidence for PET 
staging in SCLC is not yet definitive.
Their letter raises two of the most 
vexing questions regarding the role 
of PET staging in the management of 
SCLC; namely the true accuracy of PET 
staging in this setting, and the appropri-
ateness of basing treatment decisions 
on PET results when evidence-based 
treatment derives from trials performed 
in the pre-PET era using conventional 
imaging techniques.
The need for rapid initiation of 
therapy in SCLC and the fact that this 
disease is rarely managed surgically 
means that histological confirmation of 
PET staging, or conventional stag ing for 
that matter, is rarely feasible. As we point 
out, this is a significant limita tion in the 
available data regarding PET staging in 
SCLC. However, as desirable as histo-
logical confirmation may be, ultimately 
it is the correlation of stag ing with clini-
cal outcomes that mat ters most; and pro-
spective studies with excellent clinical, 
radiological, and/or histological confir-
mation of PET stag ing do exist. These 
include seven stud ies specifically ana-
lyzing individual metastatic where CT 
vs. PET findings were discordant. The 
published data are consistent in show-
ing the superi ority of PET over conven-
tional imag ing for the staging of SCLC 
using an admixture of clinical and 
pathological endpoints. These findings 
are rationally expected given the high 
FDG avidity of this rapidly proliferative 
tumor. So while the lack of consistent 
histological confirmation of PET find-
ings should be acknowledged, and while 
PET should be interpreted together with 
clinical judgement, this relative lack 
should not negate inclusion of PET find-
ings into patient management decisions.
Whether or not to base patient 
management on PET findings is a dif-
ficult question to consider because only 
limited evidence is available. The authors 
make a good point that some patients 
with limited disease in randomized tri-
als may have harbored occult metastases 
undetectable by CT scans but possibly 
detectable by PET. They argue that such 
patients may in fact benefit from con-
current thoracic radiotherapy (RT) and 
should not be denied this on the basis of 
PET scanning. This may well be correct 
(whether CREST and RTOG 0937 ulti-
mately show benefit for RT in patients 
with extensive disease or not). However, 
the converse may also be argued; that the 
patients with PET-detected occult dis-
ease are the patients least likely to ben-
efit from the addition of toxic concurrent 
RT and could be spared needless toxic-
ity. After all, the benefit of radiotherapy 
is rather modest—the meta-analysis of 
Pignon et al. revealed just a 5% improve-
ment in 3-year survival with the addition 
of concurrent RT (14% versus 9%).1 In 
other words, at the 3-year time point, 
the vast majority of patients receiving 
RT did not benefit from it, but all were 
subjected to the associated toxicity. In all 
likelihood the patients least likely to ben-
efit from RT would be those with PET-
detected extensive disease rather than 
patients who do not have PET-evident 
metastases. It is our task in the era of 
personalized medicine to tailor therapy 
as accurately as possible to individuals 
and to identify those for whom treatment 
is futile so that they are not subjected to 
pointless toxicity. Although the authors 
express concern about withholding RT 
based on PET staging, the possible ben-
efit that concurrent chemoradiotherapy 
might offer to patients downstaged by 
PET to limited disease should also not 
be forgotten. The uncertainties are the 
same as for patients who were upstaged 
by PET but with the prospect of benefit 
from the addition of RT rather than harm. 
We believe that ultimately, because no 
definitive trials exist using PET staging, 
the decision to offer or withhold concur-
rent thoracic RT from patients based on 
PET should be individualized and the 
benefit of the doubt given in favor of sur-
vival prolongation after due discussion 
with the patient.
Should PET be used to define RT 
target volumes? A single prospective trial 
designed specifically to answer this ques-
tion reported a 3% isolated nodal failure 
rate in the absence of local or distant 
recurrence.2 This suggests that PET is 
an effective imaging modality and useful 
for target delineation. Because no stud-
ies have directly compared PET with CT 
in this context, no definitive conclusions 
can be drawn, but it seems misguided to 
ignore PET findings if available when 
deciding on target volumes for chest RT.
Although we agree with Drs. 
Faivre-Finn and Lorigan, and indeed 
have stated in our review that PET data 
are not as robust in SCLC as they are in 
non small cell lung cancer, this does not 
mean that they are not valuable. In fact, 
no data suggest that conventional imag-
ing is superior to PET, and the available 
data subject to their limitations consis-
tently suggest that PET staging is supe-
rior in both sensitivity and specificity.3
In summary therefore, we are of 
the view that information from PET 
scanning adds value to the management 
of SCLC patients. However we agree 
with Drs. Faivre-Finn and Lorigan that 
data regarding PET in SCLC are not yet 
definitive, and therefore, sound clini-
cal judgment should be exercised when 
integrating PET information into clinical 
decisions regarding individual patients.
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